THE NATIONAL HEALTH AUTHORITY BUNDESAMT FÜR GESUNDHEIT APPROVES REIMBURSEMENT OF XIFAXAN® 550 IN SWITZERLAND

LONDON, UK, Tuesday 1 September 2015, 12:00 GMT+1 – Norgine B.V. today announced that the National Health Authority in Switzerland, Bundesamt für Gesundheit, has approved the reimbursement of XIFAXAN® 550 (rifaximin-α 550mg) as an add-on therapy to non-absorbable disaccharides as it can reduce the recurrence of episodes of overt hepatic encephalopathy in patients aged 18 years or older with hepatic cirrhosis. Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease. It is estimated that 740,000 people in Europe are affected by cirrhosis, of which hepatic encephalopathy is a common complication.[i], [ii], [iii], [iv]
This positive decision acknowledges that XIFAXAN® 550 can reduce the relative risk of recurrent episodes of hepatic encephalopathy by 58%, with an associated 50% reduction of hospitalisations.[v] Furthermore, it supports the value of XIFAXAN® 550 (rifaximin-α 550mg) as a much needed therapy when it is known there is currently no cure for hepatic encephalopathy apart from liver transplantation.
XIFAXAN® 550 is reimbursed in Australia, Germany, Ireland, Luxembourg, Scotland, Sweden and United Kingdom. Norgine and Alfa Wassermann are continuing to work with other Health Technology Assessment bodies across Europe to ensure patients have appropriate access to this important medicine.
Peter Martin, Chief Operating Officer Norgine, commented, "We are pleased that Bundesamt für Gesundheit has approved the reimbursement of XIFAXAN® 550, acknowledging the value that this medicine can bring to patients and their families. Hepatic encephalopathy has a huge impact on the lives of patients, their families and careers, XIFAXAN® 550 can help to reduce the burden that repeated hepatic encephalopathy episodes bring."

Norgine currently holds marketing rights for XIFAXAN® 550 (known as TARGAXAN®▼ 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, France, Germany, Luxembourg, MENA, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, Switzerland and United Kingdom.

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

As part of a multi-year asset offload, AstraZeneca has divested most of its global rights to constipation med Movantik to RedHill Biopharma.

Tazverik could beat consensus estimates thanks to current launch signs and an early FDA decision date for a label expansion, one analyst says.